Intuitive Surgical’s Slower Procedure Growth Weighs on Shares Despite Strong Results

Strong Results Fail to Offset Growth Concerns

Intuitive Surgical (ISRG) delivered better-than-expected second-quarter results, but the market reaction highlighted growing investor sensitivity to signs of slowing procedure growth.

The robotic surgery leader reported revenue of $2.89 billion, up 19% year over year and ahead of analyst expectations of $2.82 billion. Adjusted earnings per share reached $2.80, exceeding the consensus estimate of $2.51. Despite the strong performance, shares fell sharply as investors focused on a more cautious growth outlook.

Key Points

• Intuitive Surgical reported second-quarter revenue of $2.89 billion and adjusted EPS of $2.80, both above Wall Street estimates.
• U.S. procedure growth slowed to 12% from 14% in the prior quarter, raising concerns about future demand trends.
• The company maintained full-year procedure growth guidance but indicated results would likely land near the midpoint of its forecast range.

What Drove the Market Reaction?

Although Intuitive Surgical delivered another quarter of double-digit growth, investors focused on procedure trends rather than headline earnings.

U.S. da Vinci procedure growth slowed to 12% during the quarter, down from 14% in the first quarter and below Wall Street expectations. Management attributed the moderation to deferred elective procedures, changes in patient insurance coverage following the expiration of enhanced Affordable Care Act subsidies, and lower bariatric surgery volumes as some patients increasingly opt for GLP-1 weight-loss medications.

The company maintained its forecast for worldwide da Vinci procedure growth of 13.5% to 15.5% in 2026 but said results are expected to be near the midpoint of that range. That implied growth rate fell below analyst expectations, contributing to the negative investor reaction.

Several analysts noted that expectations had become elevated after Intuitive raised guidance earlier in the year, leading some investors to anticipate another upward revision.

How Did Intuitive Surgical Perform in the Quarter?

Operationally, the quarter remained strong across most key metrics.

Worldwide procedures across the da Vinci and Ion platforms increased approximately 16% year over year. Da Vinci procedures rose roughly 15%, while Ion procedures grew 36%.

The company placed 468 da Vinci surgical systems during the quarter, compared with 395 a year earlier. That included 246 placements of the newer da Vinci 5 platform. The installed base of da Vinci systems increased 12% to 11,710 systems, while the Ion installed base expanded 21% to 1,096 systems.

Revenue growth was broad-based. Systems revenue rose to $685 million from $575 million a year ago, supported by higher placements, increased average selling prices, and greater leasing activity. Instruments and accessories revenue increased 18% to $1.73 billion, while recurring revenue climbed 19% to $2.47 billion and represented 85% of total revenue.

Profitability also improved. Non-GAAP gross margin reached 70.0%, up from 67.9% a year ago, prompting management to raise its full-year gross margin outlook to 68%–69% of revenue.

What Matters Most Going Forward?

Investors are now focused on whether the slowdown in U.S. procedure growth proves temporary or signals a more persistent trend.

Management emphasized that medically necessary procedures remain resilient and indicated that deferred cases are expected to return over time. Outside the United States, procedure growth accelerated to 20%, supported by strength across Europe, Asia, and other international markets.

Competition is also attracting attention. Johnson & Johnson (JNJ) is preparing to launch its Ottova robotic surgery system for soft-tissue procedures and is targeting regulatory clearance by year-end. Meanwhile, analysts highlighted increasing competition from Chinese robotic surgery companies, particularly in the Chinese market where Intuitive faced weaker system placements and pricing pressure.

Investors will also be watching whether adoption of the da Vinci 5 platform, growth in the Ion business, and international expansion can offset softer trends in certain U.S. procedure categories.

What It Means for Investors

The sharp selloff illustrates how much investor expectations influence market reactions, particularly for companies with premium valuations.

While Intuitive Surgical delivered strong earnings growth, revenue expansion, improving margins, and continued system adoption, investors focused on the prospect of slower procedure growth in the second half of the year.

For those following ISRG stock news and broader market news today, the key question is whether recent procedure softness reflects temporary headwinds related to insurance coverage and elective surgery timing or a more sustained slowdown in demand.

Management and several analysts characterized the slowdown as temporary, but future procedure trends are likely to remain the primary driver of investor sentiment.

Conclusion

Intuitive Surgical reported another strong quarter, surpassing Wall Street expectations on both revenue and earnings while continuing to expand its installed base and recurring revenue streams.

However, slowing U.S. procedure growth and a full-year outlook that implied more moderate growth ahead overshadowed the earnings beat. As a result, investors shifted their attention from profitability to growth durability, sending ISRG stock sharply lower.

The company’s ability to reaccelerate procedure growth while defending its leadership position in robotic surgery will remain a central focus for the market in the quarters ahead.

FAQs

Why did Intuitive Surgical stock fall despite beating earnings estimates?

Investors focused on slowing U.S. procedure growth and a full-year outlook that implied more moderate growth in the second half of 2026.

How much revenue did Intuitive Surgical report in the second quarter?

The company reported second-quarter revenue of $2.89 billion, up 19% from a year earlier.

What was Intuitive Surgical’s earnings per share in Q2?

Adjusted earnings per share were $2.80, exceeding analyst expectations of $2.51.

What is slowing procedure growth at Intuitive Surgical?

Management cited deferred elective procedures, changes in insurance coverage, and reduced bariatric surgery volumes as contributing factors.

Who are Intuitive Surgical’s emerging competitors?

Johnson & Johnson is preparing to launch its Ottova robotic surgery system, while Chinese robotic surgery companies are increasing competition in China.

This article was created with AI assistance and reviewed by an editor. For details, please refer to our Terms of Use.

Explore Research with Stock Investor

For readers evaluating long-term market opportunities, Stock Investor is SharperTrades’ investing platform built around portfolio management, market research, and AI-assisted analysis. Members receive research reports, portfolio updates, conviction tracking, and educational insights designed to support disciplined investing decisions.

Follow the Market with SharperTrades

SharperTrades offers additional ways to stay connected to the market. Block Orders tracks institutional activity and highlights active trade setups and price behavior across long and short opportunities. For options-focused traders, Essential Option Income provides a structured approach to income strategies.

Learn More with SharperTrades Academy

If you value the clear, explanatory approach of Market Brief, explore SharperTrades Academy, where we publish in-depth content and structured programs covering technical analysis, options, and risk management to help you better interpret market behavior.

Think More Clearly with SteadyCapital

SteadyCapital is SharperTrades' AI-powered behavioral investing app designed to help investors make better decisions. Review investment ideas, run company valuations, compare businesses, challenge your assumptions, and use the AI Coach to think more clearly before making important investment decisions.

Risk Disclosure

All content is provided for educational purposes only and does not constitute investment advice. Trading involves risk, and past performance is not indicative of future results. Please review our full Risk Disclosure for additional information.